New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab

Jeffrey S. Rose; Tanios S. Bekaii-Saab

doi:10.2147/OTT.S10188

New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab

Jeffrey S. Rose, Tanios S. Bekaii-Saab

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

Original language	English (US)
Pages (from-to)	21-26
Number of pages	6
Journal	OncoTargets and Therapy
Volume	4
DOIs	https://doi.org/10.2147/OTT.S10188
State	Published - 2011

Keywords

Adenocarcinoma
Chemotherapy
Gastric
Gastroesophageal
Trastuzumab

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.2147/OTT.S10188

Cite this

@article{1936b3ee179d4a3aa4dd6915b3ad9f9f,

title = "New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab",

abstract = "Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.",

keywords = "Adenocarcinoma, Chemotherapy, Gastric, Gastroesophageal, Trastuzumab",

author = "Rose, {Jeffrey S.} and Bekaii-Saab, {Tanios S.}",

year = "2011",

doi = "10.2147/OTT.S10188",

language = "English (US)",

volume = "4",

pages = "21--26",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - New developments in the treatment of metastatic gastric cancer

T2 - Focus on trastuzumab

AU - Rose, Jeffrey S.

AU - Bekaii-Saab, Tanios S.

PY - 2011

Y1 - 2011

N2 - Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

AB - Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.

KW - Adenocarcinoma

KW - Chemotherapy

KW - Gastric

KW - Gastroesophageal

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84859265817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859265817&partnerID=8YFLogxK

U2 - 10.2147/OTT.S10188

DO - 10.2147/OTT.S10188

M3 - Review article

C2 - 21552412

AN - SCOPUS:84859265817

SN - 1178-6930

VL - 4

SP - 21

EP - 26

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -

New developments in the treatment of metastatic gastric cancer: Focus on trastuzumab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this